A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD
Sponsored by Amicus Therapeutics
About this trial
Last updated 2 years ago
Study ID
ATB200-07
Status
Active, not recruiting
Type
Interventional
Phase
Phase 3
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 2 years ago
What is this trial about?
This is a multicenter, international open-label extension study of ATB200/AT2221 in adult
subjects with late-onset Pompe disease (LOPD) who completed Study ATB200-03.
What are the participation requirements?
Inclusion Criteria
1. Subject must have completed Study ATB200-03.
Exclusion Criteria
1. Subject plans to receive gene therapy or participate in another interventional study for Pompe disease.
2. Subject, if female, is pregnant or breastfeeding.
3. Subject, whether male or female, is planning to conceive a child during the study.